Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Wednesday . The stock had previously closed at $30.58, but opened at $33.65. Nanobiotix shares last traded at $33.04, with a volume of 8,075 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NBTX. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. TD Cowen began coverage on shares of Nanobiotix in a research report on Friday, February 6th. They issued a “buy” rating for the company. Guggenheim boosted their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Nanobiotix Price Performance

The business’s 50 day moving average price is $23.21 and its 200-day moving average price is $19.81.

Institutional Trading of Nanobiotix

Several institutional investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC bought a new position in shares of Nanobiotix in the 4th quarter worth about $390,000. Marshall Wace LLP bought a new position in Nanobiotix in the fourth quarter worth about $220,000. Optiver Holding B.V. acquired a new position in Nanobiotix in the third quarter valued at approximately $101,000. Finally, Royal Bank of Canada grew its holdings in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.